Market revenue in 2023 | USD 1,582.8 million |
Market revenue in 2030 | USD 2,114.0 million |
Growth rate | 4.2% (CAGR from 2023 to 2030) |
Largest segment | Biopharmaceuticals |
Fastest growing segment | Biopharmaceuticals |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Pharmaceuticals, Biopharmaceuticals |
Key market players worldwide | Boehringer Ingelheim, Novartis AG ADR, Regeneron Pharmaceuticals Inc, Pfizer Inc, Bristol-Myers Squibb Co, Roche Holding AG, UCB SA, Johnson & Johnson, Amgen Inc, AbbVie Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to rheumatoid arthritis therapeutics market will help companies and investors design strategic landscapes.
Biopharmaceuticals was the largest segment with a revenue share of 88.74% in 2023. Horizon Databook has segmented the Germany rheumatoid arthritis therapeutics market based on pharmaceuticals, biopharmaceuticals covering the revenue growth of each sub-segment from 2018 to 2030.
The Germany rheumatoid arthritis therapeutics market is marked by comprehensive research initiatives and long-term observational studies aimed at understanding disease progression and treatment outcomes. One significant effort is the Rheumatoide Arthritis: Beobachtung der Biologika-Therapie, or the RABBIT study.
This study is conducted by the Pharmacoepidemiology group of the Epidemiology Unit at the German Rheumatism Research Center (Deutsches Rheuma-Forschungszentrum) in Berlin. The RABBIT study focuses on observing the disease and treatment courses of over 17,000 RA patients treated by approximately 400 rheumatologists across Germany.
This extensive and long-term observational approach provides valuable insights into real-world treatment practices, effectiveness of therapies, and patient outcomes, thereby informing clinical decisions and enhancing patient care.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany rheumatoid arthritis therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Germany rheumatoid arthritis therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account